Current therapeutic modalities and chemopreventive role of natural products in liver cancer: Progress and promise

Singh, Amit Kumar; Singh, Sweta; Kumar, Ramesh; Kumar, Shashank; Senapati, Sabyasachi; Pandey, Abhay K.

doi:10.4254/wjh.v15.i1.1

Cited by 23 publications

(8 citation statements)

References 141 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The occurrence and development of HCC is a complex process, often involving the aberrant activation of multiple signaling pathways. Previous studies have revealed a close association between the dysregulation of NF-κB, TGF-β, Wnt/β-Catenin, and JAK-STAT signaling pathways and the progression of HCC ( 16 , 155 , 156 ). The aberrant activation of the JAK-STAT signaling pathway contributes to hepatocyte development and progression ( 157 ).…”

Section: Critical Signaling Pathways Related To Tils In Hccmentioning

confidence: 99%

Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances

Wang,

Yuan,

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

The incidence of hepatocellular carcinoma (HCC) ranks first among primary liver cancers, and its mortality rate exhibits a consistent annual increase. The treatment of HCC has witnessed a significant surge in recent years, with the emergence of targeted immune therapy as an adjunct to early surgical resection. Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) has shown promising results in other types of solid tumors. This article aims to provide a comprehensive overview of the intricate interactions between different types of TILs and their impact on HCC, elucidate strategies for targeting neoantigens through TILs, and address the challenges encountered in TIL therapies along with potential solutions. Furthermore, this article specifically examines the impact of oncogenic signaling pathways activation within the HCC tumor microenvironment on the infiltration dynamics of TILs. Additionally, a concise overview is provided regarding TIL preparation techniques and an update on clinical trials investigating TIL-based immunotherapy in solid tumors.

show abstract

Section: Critical Signaling Pathways Related To Tils In Hccmentioning

confidence: 99%

Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances

Wang,

Yuan,

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…With regard to the reversal of NAFLD/NASH, curcumin alleviates dyslipidemia and liver fat accumulation in NAFLD rats by upregulating SIRT3 to improve mitochondrial function (Du et al, 2022) and TNF-α (Tong et al, 2021). As for the prevention of HCC, previous literature has reviewed the protective actions of curcumin, particularly when applied in nanoformulations and coadministration (Ghobadi & Asoodeh, 2023;Shelash Al-Hawary et al, 2023;Singh et al, 2023).…”

Section: Curcuminmentioning

confidence: 99%

“…Tong et al demonstrated that curcumin moderated NAFLD/NASH progression by inhibiting macrophage M1 polarization and the secretion of inflammatory factors such as IL‐1β and TNF‐α (Tong et al, 2021). As for the prevention of HCC, previous literature has reviewed the protective actions of curcumin, particularly when applied in nanoformulations and coadministration (Ghobadi & Asoodeh, 2023; Shelash Al‐Hawary et al, 2023; Singh et al, 2023). Furthermore, several emerging molecular mechanisms related to curcumin's treatment of HCC should be mentioned.…”

Section: Mechanisms Of Polyphenolic Compounds Protect Against Hepatic...mentioning

confidence: 99%

Human diet‐derived polyphenolic compounds and hepatic diseases: From therapeutic mechanisms to clinical utilization

Hu,

Zhang,

Wei

et al. 2023

Phytotherapy Research

View full text Add to dashboard Cite

This review focuses on the potential ameliorative effects of polyphenolic compounds derived from human diet on hepatic diseases. It discusses the molecular mechanisms and recent advancements in clinical applications. Edible polyphenols have been found to play a therapeutic role, particularly in liver injury, liver fibrosis, NAFLD/NASH, and HCC. In the regulation of liver injury, polyphenols exhibit anti‐inflammatory and antioxidant effects, primarily targeting the TGF‐β, NF‐κB/TLR4, PI3K/AKT, and Nrf2/HO‐1 signaling pathways. In the regulation of liver fibrosis, polyphenolic compounds effectively reverse the fibrotic process by inhibiting the activation of hepatic stellate cells (HSC). Furthermore, polyphenolic compounds show efficacy against NAFLD/NASH by inhibiting lipid oxidation and accumulation, mediated through the AMPK, SIRT, and PPARγ pathways. Moreover, several polyphenolic compounds exhibit anti‐HCC activity by suppressing tumor cell proliferation and metastasis. This inhibition primarily involves blocking Akt and Wnt signaling, as well as inhibiting the epithelial‐mesenchymal transition (EMT). Additionally, clinical trials and nutritional evidence support the notion that certain polyphenols can improve liver disease and associated metabolic disorders. However, further fundamental research and clinical trials are warranted to validate the efficacy of dietary polyphenols.

show abstract

“…1 Although surgical resection is the primary choice for treating resectable HCC, the recurrence rate within 5 years postsurgery remains alarmingly high, reaching up to 70% and significantly impacting the long-term survival of patients. 2,3 While certain factors such as tumor size (≥5 cm), number of tumors (≥3), unclear tumor boundaries, and elevated AFP value (≥400 ng/mL) have been associated with postoperative recurrence in liver cancer, many early-stage patients lacking these factors still face a poor prognosis. 4 Microvascular invasion, recognized as the earliest manifestation of liver cancer metastasis, serves as an independent risk factor for tumor recurrence and metastasis following resection.…”

Section: Introductionmentioning

confidence: 99%

“…In 2020 alone, over 900 000 new cases of liver cancer were reported, resulting in 800 000 deaths worldwide 1 . Although surgical resection is the primary choice for treating resectable HCC, the recurrence rate within 5 years postsurgery remains alarmingly high, reaching up to 70% and significantly impacting the long‐term survival of patients 2,3 . While certain factors such as tumor size (≥5 cm), number of tumors (≥3), unclear tumor boundaries, and elevated AFP value (≥400 ng/mL) have been associated with postoperative recurrence in liver cancer, many early‐stage patients lacking these factors still face a poor prognosis 4 .…”

Section: Introductionmentioning

confidence: 99%

Protein profiles reveal MSH6/MSH2 as a potential biomarker for hepatocellular carcinoma with microvascular invasion

Hong,

Zhang,

Liu

et al. 2023

Hepatology Research

View full text Add to dashboard Cite

AimMicrovascular invasion (MVI) is an independent risk factor for postoperative recurrence and metastasis in hepatocellular carcinoma (HCC). However, the specific protein expression profiles that differentiate HCC with MVI from those without MVI remain unclear.MethodsThe profiles of proteins in early‐stage HCC tissues and normal liver tissues were characterized by quantitative proteomics techniques. Immunohistochemical (IHC) staining was performed on tissue microarrays from 80 HCC patients to assess the expression of MSH2 and MSH6. Cell counting and colony formation, migration and invasion assays were performed in vitro.ResultsWe identified 5164 proteins in both HCC tissues and adjacent normal liver tissues. As compared to HCC without MVI, 148 upregulated proteins and 97 downregulated proteins were found in HCC with MVI. Particularly noteworthy was the remarkable upregulation of MSH6/MSH2 among these dysregulated proteins in HCC with MVI. Further validation through bioinformatics prediction and IHC confirmed the elevated expression of MSH6/MSH2, which correlated with aggressive disease characteristics and poor prognosis. Receiver operating characteristic curve analyses demonstrated a substantial area under curve of 0.761 (specificity: 71.79%, sensitivity: 73.17%) for the combined use of MSH6/MSH2. Knockdown of MSH6/MSH2 significantly inhibited HCC cell proliferation and invasion in vitro.ConclusionsOur study establishes MSH6 or MSH2 as an oncogene that is prominently overexpressed during HCC progression which provides new targets for HCC with MVI.This article is protected by copyright. All rights reserved.

show abstract

Current therapeutic modalities and chemopreventive role of natural products in liver cancer: Progress and promise

Cited by 23 publications

References 141 publications

Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances

Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances

Human diet‐derived polyphenolic compounds and hepatic diseases: From therapeutic mechanisms to clinical utilization

Protein profiles reveal MSH6/MSH2 as a potential biomarker for hepatocellular carcinoma with microvascular invasion

Contact Info

Product

Resources

About